REVIEW article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1589341
This article is part of the Research TopicLymphocytes and Autoimmune Disease: from molecular mechanism to clinical implicationsView all 11 articles
Emerging Therapeutic Potential and Clinical Challenges
Provisionally accepted
- 1Department of pharmacy, Chengdu Seventh People's Hospital (Affiliated Cancer Hospital of Chengdu Medical College),, Chengdu, Sichuan Province, China
- 2Department of pharmacy, Sichuan Provincial Woman's and Children's Hospital & The Affliated Women's and Children's Hospital of Chengdu Medical College,, Sichuan Provincial Hospital for Women and Children, Chengdu, China
- 3Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, China
- 4School of Pharmacy, Southwest Medical University, Luzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Autoimmune diseases (AIDs) are conditions where the immune system mistakenly attacks self-antigens, leading to tissue and organ damage. The exact mechanisms underlying AIDs pathogenesis remain unclear, and effective treatments are currently limited, posing significant therapeutic challenges. Recent studies suggest that targeting T cell immune metabolism could be a promising approach for treating AIDs.Repurposed type 2 diabetes mellitus (T2DM) medications, which modulate immune metabolic processes, have shown potential in various inflammatory conditions. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a novel class of oral antidiabetic agents, not only regulate metabolic dysfunction but also offer protective effects on the heart and kidneys. Emerging preclinical evidence indicates that SGLT2 inhibitors possess immunomodulatory properties, highlighting their potential in enhancing T cellmediated autoimmune therapy. Clinical studies further validate that SGLT2 inhibitors significantly reduce the risk of chronic kidney disease (CKD) progression in nondiabetic patient groups, such as those with chronic glomerulonephritis like IgA nephropathy. This review aims to evaluate current preclinical and clinical research on the impact of SGLT2 inhibitors on the immune system and explore their mechanisms of action relevant to treating AIDs.
Keywords: ：SGLT2 inhibitors, Autoimmune Diseases, T cells, metabolic reprogramming, Inflammatory response ABBREVIATIONS：AID, Autoimmune disease, T2DM, type 2 diabetes mellitus, CKD, chronic kidney disease, Tregs, regulatory T cells
Received: 07 Mar 2025; Accepted: 03 Jun 2025.
Copyright: © 2025 Luo, Zhang, Li, Su, Gong, Huang, Li and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Liaoyun Zhang, Department of pharmacy, Sichuan Provincial Woman's and Children's Hospital & The Affliated Women's and Children's Hospital of Chengdu Medical College,, Sichuan Provincial Hospital for Women and Children, Chengdu, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.